Effect of oral ALA supplementation on oxidative stress and insulin sensitivity among overweight/obese adults: A double-blinded, randomized, controlled, cross-over intervention trial

摘要

Recent studies show that oxidative stress may be the unifying mechanism in the development of major obesity-related comorbidities [1,2]. We designed the current double-blind, randomized controlled intervention trial to assess whether oral ALA supplementation will lower the risk of CVD by decreasing the level of oxidative stress (indexed by OxLDL and 8-iso-PGF2a) or improving insulin sensitivity (indexed by HOMA) in overweight/obese subjects. We screened 347 overweight Han Chinese and identified 166 subjects meeting our inclusion criteria from a physical examination setting. The inclusion criteria were: 1) body mass index (BMI)>25kg/m~2; 2) 18-60 years; 3) not on any antioxidant vitamin supplement, and 4) having at least one of borderline hypertension (130 mm Hg 240 mg/dlorHDL-C<40 mg/dl), or impaired fasting glucose (fasting glucose levels between 6.1 and 7.0 mmol/l). Those with history of hypertension, diabetes, coronary heart disease, cancer or chronic liver disease, or psychiatric problems were excluded. One hundred and three subjects signed inform consent forms. Age and sex of participants did not significantly differ from the people who declined.